Acaris announces development and licensing agreement with City Technology LimitedOctober 14, 2002Cambridge, UK, 14 October 2002: Acaris Healthcare Solutions plc ("Acaris" or "the Company") today announced that it has entered into a product development and technology licensing agreement with City Technology Limited (Portsmouth, UK: "City") to develop a new range of products to detect and monitor hazardous biological agents used in industrial environments. Under the terms of this latest agreement, Acaris will use its proprietary technology base to develop products for City's industrial market. The first products to evolve from this programme will be for monitoring allergenic agents in manufacturing environments. In the USA the Occupational Safety & Health Administration (OSHA) estimates that 11 million workers are at risk from Occupational Asthma arising as a result of high levels of allergens in the working environment. Similarly, the UK Health and Safety Commission (HSC) has set a target to reduce cases of Occupational Asthma by 30% by 2010. As part of the agreement, City has acquired an exclusive world-wide licence for these products in exchange for royalties payable to Acaris on sales and has also taken a first equity stake in Acaris. Dr Ramin Pirzad, Managing Director of Acaris, commented: "This is a very important and exciting alliance for Acaris allowing the company to expand its technology and know-how into wider target markets, in this case, the industrial sector. This initial opportunity sees the start of a potential new pipeline of products for this sector." Kevin Breen, CEO of City, commented: "We are very pleased to work with Acaris who have significant proprietary technology which will enable us to offer a wider range of sensors to our industrial instrumentation customers. We believe that the joint development work between City and Acaris will result in a significant contribution to industrial safety world-wide." Charles Consultants |
|||||||||||||||||||||
| Related Asthma Current Events and Asthma News Articles Exposures to metals and diesel emissions in air linked to respiratory symptoms in children Exposure shortly after birth to ambient metals from residential heating oil combustion and particles from diesel emissions are associated with respiratory symptoms in young inner city children. Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later New research presents strong evidence that the "synergistic" effect of early-life exposure to both outdoor traffic-related pollution and indoor endotoxin causes more harm to developing lungs than one or the other exposure alone. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests. Ancestry attracts, but love is blind People preferentially marry those with similar ancestry, but their decisions are not necessarily based on hair, eye or skin colour. Common plastics chemicals linked to ADHD symptoms Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Asthma a significant risk factor for complications in children with H1N1 A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu. Mother's Depression a Risk Factor in Childhood Asthma Symptoms, Study Suggests Asthma symptoms can worsen in children with depressed mothers, according to research from Johns Hopkins Children's Center published online in the Journal of Pediatric Psychology. Sweet -- sugared polymer a new weapon against allergies and asthma Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. Pivotal study for PSD502 -- the first potential treatment for premature ejaculation At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. More Asthma Current Events and Asthma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||